First Header Logo Second Header Logo

Connection

Steven Feldman to Quality of Life

Back to Details
This is a "connection" page, showing publications Steven Feldman has written about Quality of Life.
Steven Feldman
Connection Strength
7.880
Quality of Life
  1. Svoboda SA, Ghamrawi RI, Owusu DA, Feldman SR. Treatment Goals in Psoriasis: Which Outcomes Matter Most? Am J Clin Dermatol. 2020 Aug; 21(4):505-511.
    View in: PubMed
    Score: 0.477
  2. Seger EW, Wechter T, Strowd L, Feldman SR. Relative efficacy of systemic treatments for atopic dermatitis. J Am Acad Dermatol. 2019 Feb; 80(2):411-416.e4.
    View in: PubMed
    Score: 0.421
  3. Skaggs RL, Hix E, Huang KE, Feldman SR. Characterization of Patients' Quality of Life and Experience in the Course of Acne Treatment. Skinmed. 2017; 15(6):431-435.
    View in: PubMed
    Score: 0.397
  4. Feldman SR, Malakouti M, Koo JY. Social impact of the burden of psoriasis: effects on patients and practice. Dermatol Online J. 2014 Aug 17; 20(8).
    View in: PubMed
    Score: 0.316
  5. Moustafa F, Lewallen RS, Feldman SR. The psychological impact of rosacea and the influence of current management options. J Am Acad Dermatol. 2014 Nov; 71(5):973-80.
    View in: PubMed
    Score: 0.313
  6. Cresce ND, Davis SA, Huang WW, Feldman SR. The quality of life impact of acne and rosacea compared to other major medical conditions. J Drugs Dermatol. 2014 Jun; 13(6):692-7.
    View in: PubMed
    Score: 0.311
  7. Feldman SR. Disease burden and treatment adherence in psoriasis patients. Cutis. 2013 Nov; 92(5):258-63.
    View in: PubMed
    Score: 0.299
  8. Barnes LE, Levender MM, Fleischer AB, Feldman SR. Quality of life measures for acne patients. Dermatol Clin. 2012 Apr; 30(2):293-300, ix.
    View in: PubMed
    Score: 0.262
  9. Dunn LK, O'Neill JL, Feldman SR. Acne in adolescents: quality of life, self-esteem, mood, and psychological disorders. Dermatol Online J. 2011 Jan 15; 17(1):1.
    View in: PubMed
    Score: 0.246
  10. Lott R, Taylor SL, O'Neill JL, Krowchuk DP, Feldman SR. Medication adherence among acne patients: a review. J Cosmet Dermatol. 2010 Jun; 9(2):160-6.
    View in: PubMed
    Score: 0.236
  11. Kulkarni AS, Horn E, Balkrishnan R, Feldman S. Severity levels in psoriasis: a separate 'very severe' category not required. J Dermatolog Treat. 2009; 20(1):48-51.
    View in: PubMed
    Score: 0.214
  12. Garduno J, Bhosle MJ, Balkrishnan R, Feldman SR. Measures used in specifying psoriasis lesion(s), global disease and quality of life: a systematic review. J Dermatolog Treat. 2007; 18(4):223-42.
    View in: PubMed
    Score: 0.186
  13. Balkrishnan R, McMichael AJ, Hu JY, Camacho FT, Shew KR, Bouloc A, Rapp SR, Feldman SR. Correlates of health-related quality of life in women with severe facial blemishes. Int J Dermatol. 2006 Feb; 45(2):111-5.
    View in: PubMed
    Score: 0.175
  14. Feldman SR, Kimball AB, Krueger GG, Woolley JM, Lalla D, Jahreis A. Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol. 2005 Nov; 53(5):887-9.
    View in: PubMed
    Score: 0.172
  15. Stein KR, Pearce DJ, Feldman SR. The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin Cutan Med Surg. 2005 Mar; 24(1):52-7.
    View in: PubMed
    Score: 0.164
  16. Rapp SR, Feldman SR. The promise and challenge of new biological treatments for psoriasis: how do they impact quality of life? Dermatol Ther. 2004; 17(5):376-82.
    View in: PubMed
    Score: 0.151
  17. Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol. 2003 Aug; 49(2):271-5.
    View in: PubMed
    Score: 0.147
  18. Housman TS, Mellen BG, Rapp SR, Fleischer AB, Feldman SR. Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis. 2002 Dec; 70(6):327-32.
    View in: PubMed
    Score: 0.140
  19. Felix K, Unrue E, Inyang M, Cardwell LA, Oussedik E, Richardson I, Feldman SR. Patients preferences for different corticosteroid vehicles are highly variable. J Dermatolog Treat. 2020 Mar; 31(2):147-151.
    View in: PubMed
    Score: 0.113
  20. Kolli SS, Senthilnathan A, Cardwell LA, Richardson IM, Feldman SR, Pichardo RO. Hidradenitis suppurativa has an enormous impact on patients' lives. J Am Acad Dermatol. 2020 01; 82(1):236-238.
    View in: PubMed
    Score: 0.111
  21. Pona A, Haidari W, Kolli SS, Feldman SR. Diet and psoriasis. Dermatol Online J. 2019 Feb 15; 25(2).
    View in: PubMed
    Score: 0.108
  22. Glines KR, Stiff KM, Freeze M, Cline A, Strowd LC, Feldman SR. An update on the topical and oral therapy options for treating pediatric atopic dermatitis. Expert Opin Pharmacother. 2019 04; 20(5):621-629.
    View in: PubMed
    Score: 0.107
  23. Kazemi A, Cline A, Cardwell LA, Feldman SR. Psoriasis therapy and aortic inflammation - translating statistical to clinical significance. Dermatol Online J. 2018 Sep 15; 24(9).
    View in: PubMed
    Score: 0.105
  24. Feldman SR, Green L, Kimball AB, Siu K, Zhao Y, Herrera V, Nyirady J, Alexis AF. Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis. J Dermatolog Treat. 2017 Dec; 28(8):716-721.
    View in: PubMed
    Score: 0.097
  25. Patel NU, D'Ambra V, Feldman SR. Increasing Adherence with Topical Agents for Atopic Dermatitis. Am J Clin Dermatol. 2017 Jun; 18(3):323-332.
    View in: PubMed
    Score: 0.096
  26. Vera N, Patel N, Cardwell LA, Saleem M, Feldman SR. Chemical pharmacotherapy options for managing adult acne. Expert Opin Pharmacother. 2017 Feb; 18(3):263-273.
    View in: PubMed
    Score: 0.093
  27. Feldman SR, Thaçi D, Gooderham M, Augustin M, de la Cruz C, Mallbris L, Buonanno M, Tatulych S, Kaur M, Lan S, Valdez H, Mamolo C. Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016 Dec; 75(6):1162-1170.e3.
    View in: PubMed
    Score: 0.091
  28. Wehausen B, Hill DE, Feldman SR. Most people with psoriasis or rosacea are not being treated: a large population study. Dermatol Online J. 2016 Jul 15; 22(7).
    View in: PubMed
    Score: 0.090
  29. Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, Tyring S, Wolk R, Gardner A, Mebus C, Tan H, Luo Y, Gupta P, Mallbris L, Tatulych S. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol. 2016 May; 74(5):841-50.
    View in: PubMed
    Score: 0.088
  30. Rouse NC, Farhangian ME, Wehausen B, Feldman SR. The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis. Expert Rev Pharmacoecon Outcomes Res. 2015; 15(6):877-84.
    View in: PubMed
    Score: 0.086
  31. Feldman SR, Bushnell DM, Klekotka PA, Scanlon M, Martin ML, Wade SW, Yang W, Pinto L, Kircik L, Viswanathan HN. Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice. J Dermatolog Treat. 2016; 27(3):224-7.
    View in: PubMed
    Score: 0.085
  32. Moustafa FA, Sandoval LF, Feldman SR. Rosacea: new and emerging treatments. Drugs. 2014 Sep; 74(13):1457-65.
    View in: PubMed
    Score: 0.079
  33. Quandt SA, Newman JC, Pichardo-Geisinger R, Mora DC, Chen H, Feldman SR, Arcury TA. Self-reported skin symptoms and skin-related quality of life among Latino immigrant poultry processing and other manual workers. Am J Ind Med. 2014 May; 57(5):605-14.
    View in: PubMed
    Score: 0.075
  34. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, Berger TG, Bergman JN, Cohen DE, Cooper KD, Cordoro KM, Davis DM, Krol A, Margolis DJ, Paller AS, Schwarzenberger K, Silverman RA, Williams HC, Elmets CA, Block J, Harrod CG, Smith Begolka W, Sidbury R. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014 Feb; 70(2):338-51.
    View in: PubMed
    Score: 0.075
  35. Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR. Cost effectiveness of biologic therapies for plaque psoriasis. Am J Clin Dermatol. 2013 Aug; 14(4):315-26.
    View in: PubMed
    Score: 0.073
  36. Shutty BG, West C, Huang KE, Landis E, Dabade T, Browder B, O'Neill J, Kinney MA, Feneran AN, Taylor S, Yentzer B, McCall WV, Fleischer AB, Feldman SR. Sleep disturbances in psoriasis. Dermatol Online J. 2013 Jan 15; 19(1):1.
    View in: PubMed
    Score: 0.071
  37. Feldman SR, Fried RG, Herndon JH, Johnson L, Preston N, Gottschalk RW, Caveney SW. Digital videography assessment of patients' experiences using adapalene-benzoyl peroxide gel in the treatment of acne vulgaris. J Drugs Dermatol. 2012 Aug; 11(8):919-25.
    View in: PubMed
    Score: 0.069
  38. Staidle JP, Dabade TS, Feldman SR. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opin Pharmacother. 2011 Sep; 12(13):2041-54.
    View in: PubMed
    Score: 0.064
  39. Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, Ortonne JP, Gordon KB, Kimball AB. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010 Sep; 63(3):457-65.
    View in: PubMed
    Score: 0.059
  40. Uhlenhake E, Yentzer BA, Feldman SR. Acne vulgaris and depression: a retrospective examination. J Cosmet Dermatol. 2010 Mar; 9(1):59-63.
    View in: PubMed
    Score: 0.058
  41. Nolan BV, Yentzer BA, Feldman SR. A review of home phototherapy for psoriasis. Dermatol Online J. 2010 Feb 15; 16(2):1.
    View in: PubMed
    Score: 0.058
  42. Gowda S, Goldblum OM, McCall WV, Feldman SR. Factors affecting sleep quality in patients with psoriasis. J Am Acad Dermatol. 2010 Jul; 63(1):114-23.
    View in: PubMed
    Score: 0.057
  43. Feldman SR, Koo JY, Johnson LA, Preston NJ. Clobetasol propionate spray 0.05% add-on therapy to a stable regimen of biologic treatment in patients with moderate to very severe plaque psoriasis. Cutis. 2009 Oct; 84(4 Suppl):25-32.
    View in: PubMed
    Score: 0.056
  44. Pichardo R, Vallejos Q, Feldman SR, Schulz MR, Verma A, Quandt SA, Arcury TA. The prevalence of melasma and its association with quality of life in adult male Latino migrant workers. Int J Dermatol. 2009 Jan; 48(1):22-6.
    View in: PubMed
    Score: 0.053
  45. Revicki DA, Menter A, Feldman S, Kimel M, Harnam N, Willian MK. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. Health Qual Life Outcomes. 2008 Oct 02; 6:75.
    View in: PubMed
    Score: 0.053
  46. Taylor A, Pawaskar M, Taylor SL, Balkrishnan R, Feldman SR. Prevalence of pigmentary disorders and their impact on quality of life: a prospective cohort study. J Cosmet Dermatol. 2008 Sep; 7(3):164-8.
    View in: PubMed
    Score: 0.052
  47. Yelverton CB, Yentzer BA, Clark A, Pearce DJ, Balkrishnan R, Camacho FT, Boles A, Fleischer AB, Feldman SR. Home narrowband UV-B phototherapy in combination with low-dose acitretin in patients with moderate to severe psoriasis. Arch Dermatol. 2008 Sep; 144(9):1224-5.
    View in: PubMed
    Score: 0.052
  48. Quandt SA, Schulz MR, Vallejos QM, Feldman SR, Verma A, Fleischer AB, Rapp SR, Arcury TA. The association of dermatologist-diagnosed and self-reported skin diseases with skin-related quality of life in Latino migrant farmworkers. Int J Dermatol. 2008 Mar; 47(3):236-41.
    View in: PubMed
    Score: 0.050
  49. Quandt SA, Schulz MR, Vallejos QM, Feldman SR, Preisser JS, Arcury TA. Skin-related quality of life among migrant farmworkers. J Cutan Med Surg. 2008 Jan-Feb; 12(1):1-7.
    View in: PubMed
    Score: 0.050
  50. Awadalla FC, Balkrishnan R, Feldman SR. The distress of psoriasis doesn't necessarily imply good treatment adherence: a lesson from the treatment of sexually transmitted disease. J Dermatolog Treat. 2008; 19(3):132-3.
    View in: PubMed
    Score: 0.050
  51. Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol. 2008 Jan; 58(1):125-35.
    View in: PubMed
    Score: 0.049
  52. Feldman SR. Effectiveness of clobetasol propionate spray 0.05% added to other stable treatments: add-on therapy in the COBRA trial. Cutis. 2007 Nov; 80(5 Suppl):20-8.
    View in: PubMed
    Score: 0.049
  53. Pawaskar MD, Parikh P, Markowski T, McMichael AJ, Feldman SR, Balkrishnan R. Melasma and its impact on health-related quality of life in Hispanic women. J Dermatolog Treat. 2007; 18(1):5-9.
    View in: PubMed
    Score: 0.047
  54. Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006 Jun 06; 4:35.
    View in: PubMed
    Score: 0.045
  55. Rapp SR, Feldman SR, Graham G, Fleischer AB, Brenes G, Dailey M. The Acne Quality of Life Index (Acne-QOLI): development and validation of a brief instrument. Am J Clin Dermatol. 2006; 7(3):185-92.
    View in: PubMed
    Score: 0.043
  56. Krejci-Manwaring J, Kerchner K, Feldman SR, Rapp DA, Rapp SR. Social sensitivity and acne: the role of personality in negative social consequences and quality of life. Int J Psychiatry Med. 2006; 36(1):121-30.
    View in: PubMed
    Score: 0.043
  57. Hundley JL, Carroll CL, Lang W, Snively B, Yosipovitch G, Feldman SR, Jorizzo JL. Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. J Am Acad Dermatol. 2006 Feb; 54(2):217-20.
    View in: PubMed
    Score: 0.043
  58. Feldman S, Behnam SM, Behnam SE, Koo JY. Involving the patient: impact of inflammatory skin disease and patient-focused care. J Am Acad Dermatol. 2005 Jul; 53(1 Suppl 1):S78-85.
    View in: PubMed
    Score: 0.042
  59. Callender VD, Young CM, Haverstock CL, Carroll CL, Feldman SR. An open label study of clobetasol propionate 0.05% and betamethasone valerate 0.12% foams in the treatment of mild to moderate acne keloidalis. Cutis. 2005 Jun; 75(6):317-21.
    View in: PubMed
    Score: 0.042
  60. Jordan AY, Parks L, Chen SC, Higgins K, Fleischer AB, Feldman SR. Does the teratogenicity of isotretinoin outweigh its benefits? J Dermatolog Treat. 2005; 16(4):190-2.
    View in: PubMed
    Score: 0.041
  61. Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol. 2004 Nov; 51(5):704-8.
    View in: PubMed
    Score: 0.040
  62. Balkrishnan R, Manuel J, Feldman SR, Rapp SR. Measurement of health-related quality of life (HRQOL) associated with skin disease. J Am Acad Dermatol. 2004 Jul; 51(1 Suppl):S3-4.
    View in: PubMed
    Score: 0.039
  63. Parks L, Balkrishnan R, Hamel-Gariépy L, Feldman SR. The importance of skin disease as assessed by "willingness-to-pay". J Cutan Med Surg. 2003 Sep-Oct; 7(5):369-71.
    View in: PubMed
    Score: 0.037
  64. Grada A, Feldman SR, Bragazzi NL, Damiani G. Patient-reported outcomes of topical therapies in actinic keratosis: A systematic review. Dermatol Ther. 2021 03; 34(2):e14833.
    View in: PubMed
    Score: 0.031
  65. Langley RGB, Reich K, Strand V, Feldman SR, Paul C, Gordon K, Warren RB, Toth D, Nikaï E, Zhu B, Goldblum O, Edson-Heredia E, Carlier H, Burge R, Lin CY, Hollister K, Augustin M. Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. Qual Life Res. 2020 Feb; 29(2):369-380.
    View in: PubMed
    Score: 0.028
  66. Simpson EL, Guttman-Yassky E, Margolis DJ, Feldman SR, Qureshi A, Hata T, Mastey V, Wei W, Eckert L, Chao J, Arnold RJG, Yu T, Vekeman F, Suárez-Fariñas M, Gadkari A. Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis. JAMA Dermatol. 2018 08 01; 154(8):903-912.
    View in: PubMed
    Score: 0.026
  67. Mathias SD, Feldman SR, Crosby RD, Colwell HH, McQuarrie K, Han C. Measurement properties of a patient-reported outcome measure assessing psoriasis severity: The psoriasis symptoms and signs diary. J Dermatolog Treat. 2016 Aug; 27(4):322-7.
    View in: PubMed
    Score: 0.022
  68. Moradi Tuchayi S, Makrantonaki E, Ganceviciene R, Dessinioti C, Feldman SR, Zouboulis CC. Acne vulgaris. Nat Rev Dis Primers. 2015 09 17; 1:15029.
    View in: PubMed
    Score: 0.021
  69. Gerard AJ, Feldman SR, Strowd L. Quality of Life of Patients With Pyoderma Gangrenosum and Hidradenitis Suppurativa. J Cutan Med Surg. 2015 Jul-Aug; 19(4):391-6.
    View in: PubMed
    Score: 0.021
  70. Karve SJ, Feldman SR, Yentzer BA, Pearce DJ, Balkrishnan R. Imiquimod: a review of basal cell carcinoma treatments. J Drugs Dermatol. 2008 Nov; 7(11):1044-51.
    View in: PubMed
    Score: 0.013
  71. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, Van Voorhees AS, Elmets CA, Leonardi CL, Beutner KR, Bhushan R, Menter A. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008 May; 58(5):851-64.
    View in: PubMed
    Score: 0.013
  72. Price J, Bhosle M, Feldman SR, Balkrishnan R. Outcomes associated with the use of biologic agents in moderate to severe psoriasis. J Drugs Dermatol. 2007 Mar; 6(3):259-67.
    View in: PubMed
    Score: 0.012
  73. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007 Jan; 56(1):31.e1-15.
    View in: PubMed
    Score: 0.011
  74. Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, Stern RS, Feldman SR, Rolstad T. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005 Oct; 53(4):573.
    View in: PubMed
    Score: 0.011
  75. Lowe N, Feldman SR, Sherer D, Weiss J, Shavin JS, Lin YL, Foley V, Soto P. Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis. J Dermatolog Treat. 2005 Aug; 16(3):158-64.
    View in: PubMed
    Score: 0.011
  76. Carroll CL, Balkrishnan R, Feldman SR, Fleischer AB, Manuel JC. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005 May-Jun; 22(3):192-9.
    View in: PubMed
    Score: 0.010
  77. Quandt SA, Schulz MR, Feldman SR, Vallejos Q, Marín A, Carrillo L, Arcury TA. Dermatological illnesses of immigrant poultry-processing workers in North Carolina. Arch Environ Occup Health. 2005 May-Jun; 60(3):165-9.
    View in: PubMed
    Score: 0.010
  78. Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, Rolstad T, Margolis DJ. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol. 2005 Jan; 52(1):23-6.
    View in: PubMed
    Score: 0.010
  79. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004 Jun; 50(6):859-66.
    View in: PubMed
    Score: 0.010
  80. Menter MA, Krueger GC, Feldman SR, Weinstein GD. Psoriasis treatment 2003 at the new millennium: position paper on behalf of the authors. J Am Acad Dermatol. 2003 Aug; 49(2 Suppl):S39-43.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.